|
KMID : 1141720200080020080
|
|
폐쇄성폐질환
2020 Volume.8 No. 2 p.80 ~ p.82
|
|
|
Triple Therapy in Asthma
|
|
Lee Chang-Hoon
|
|
|
Abstract
|
|
|
|
Inhaled corticosteroids (ICSs) and long-acting beta2-agonists (LABAs) have been used, respectively, as the cornerstone therapy and the primary choice of add-on therapy for patients with asthma. Recently the treatment with long-acting muscarinic antagonists (LAMAs) in asthmatics also has been highlighted. In this paper, I first reviewed studies showing the role of muscarinic nervous system in asthma. Then I demonstrated the beneficial effects of LAMA in asthma from several randomized controlled trials. (RCTs) Finally, I reviewed the results of RCTs comparing clinical outcomes such as lung function and acute exacerbation risk between triple therapy and ICS/LABA in those with uncontrolled asthma. Triple therapy including LAMA is a promising therapeutic option in patients with asthma who are not controlled and at risk of exacerbation.
|
|
|
KEYWORD
|
|
|
Asthma, Long-acting muscarinic antagonist
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|